Similar, a TCGA data analysis for 234 ATG genes in patients with prostate cancer reveals that 5 ATGs (FAM215A, FDD, MYC, RHEB, and ATG16L1) can be used as a poor prognostic autophagy signature for overall survival, whereas 22 ATG genes (ULK2, NLRC4, MAPK1, ATG4D, MAPK3, ATG2A, ATG9B, FOXO1, PTEN, HDAC6, PRKN, HSPB8, P4HB, MAP2K7, MTOR, RHEB, TSC1, BIRC5, RGS19, RAB24, PTK6, and NRG2) can be used as a signature model for unfavorable DFS [29]. This evidence concerns the gene MTOR and prostate carcinoma.